A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary cancer.

被引：0
|
作者：
Shen, Jie
Kong, Weiwei
Zhu, Sihui
Liu, Baorui
机构：
[1] Nanjing Univ, Affiliated Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[2] Nanjing Univ, Comprehens Canc Ctr, Drum Tower Hosp, Med Sch, Nanjing, Peoples R China
[3] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[4] Nanjing Univ, Comprehens Canc Ctr, Med Sch, Clin Canc Inst,Drum Tower Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4077
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer
    Zhou, Mingzhen
    Jin, Yuncheng
    Zhu, Sihui
    Xu, Chen
    Li, Lin
    Liu, Baorui
    Shen, Jie
    CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2024, 13 (01)
  • [2] A phase II study to evaluate the safety and efficacy of anlotinib combined with penpulimab for advanced refractory biliary tract cancer.
    He, Xiaojun
    Tan, Kai
    Du, Xilin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS582 - TPS582
  • [3] A phase II study to evaluate the efficacy and safety of camrelizumab plus famitinib in advanced or metastatic thyroid cancer.
    Ji, Dongmei
    Shen, Weina
    Kuang, Muyu
    Liu, Ying
    Li, Huajun
    Wang, Yu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] A phase II study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer.
    Lv, Dongqing
    Wu, Guixian
    Lin, Xiaomai
    Lin, Ling
    Pan, Weijia
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Efficacy and safety of anlotinib in the treatment of lung cancer.
    Zhou, Xinliang
    Dou, Yan
    Jiang, Da
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer.
    Song, Yang
    Liu, Lili
    Min, Jie
    You, Xianghui
    Yang, Xue
    Zhang, Feng
    Huang, Xiaofeng
    Liao, Chenggong
    Shi, Hong
    Su, Haichuan
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 194 - 194
  • [7] Safety, efficacy, pharmacokinetics of uliledlimab alone or combined with toripalimab in advanced solid tumor: Initial results of a phase I/II study.
    Zhou, Qing
    Wu, Lin
    Cui, Jiuwei
    Jiang, Bo
    Yao, Yu
    Zhang, Jian
    Zhao, Mingfang
    Dong, Xiaorong
    Liu, Anwen
    Ma, Rui
    Du, Yingying
    Wang, Huijuan
    Wang, Buhai
    Hu, Xiaohua
    Pan, Hongming
    Zhang, Haibo
    Zhao, Yiqiang
    Meng, Yuan
    Zhu, Andrew X.
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study
    Chen, Jia-ying
    Huang, Nai-si
    Wei, Wen-jun
    Hu, Jia-qian
    Cao, Yi-ming
    Shen, Qiang
    Lu, Zhong-wu
    Wang, Yu-long
    Wang, Yu
    Ji, Qing-hai
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (12) : 7172 - 7180
  • [9] The efficacy and safety of anti-PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.
    Chen, Jiaying
    Ji, Qinghai
    Wang, Yu
    Huang, Naisi
    Hu, Jiaqian
    Wei, Wenjun
    Huang, Caiping
    Shen, Qiang
    Li, Duanshu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study
    Jia-ying Chen
    Nai-si Huang
    Wen-jun Wei
    Jia-qian Hu
    Yi-ming Cao
    Qiang Shen
    Zhong-wu Lu
    Yu-long Wang
    Yu Wang
    Qing-hai Ji
    Annals of Surgical Oncology, 2023, 30 : 7172 - 7180
12345